



# Similar Compounds Show Similar Activities- Is This True for Compound Combinations?

Sarita Lee, Rajarshi Guha, Lu Chen

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850

## Introduction

### Drug Combination and Synergy

- Drug combinations are used to treat many medical conditions such as: HIV, malaria, and cancer
- Sometimes the combined effect of drugs is different than their individual effects Response Matrix
- Better effect: synergism
- Same effect: additive
- Worse effect: antagonism

### **Combination Screening**

- Traditionally, screening for drug combinations is slow process
- Since NCATS has high throughput screening, data for thousands of drug combinations can be generated quickly
- Presents opportunity to do large-scale analysis

### **Metrics to Measure Synergy**

- Synergy is quantified with respect to a model of additivity <sup>1</sup>
- Three Models:
- 1. Highest Single Agent (HSA)
- 2. Bliss Independence Model
- 3. Loewe Additivity Model
- Used Bliss Independence Modelconvenient and more robust in a high throughput screening setting
- Synergistic- more blue; Antagonistic more red

#### Similarity Property Principle (SPP)

- "Similar compounds have similar properties" 2,3
- Want to know if this is true for drug combinations


### Questions

- 1. What are metrics for dissimilarity between responses?
- 2. Does chemical structure correlate to response? Synergy?
- 3. Does dose response correlate to response? Synergy?


# Q1: Metrics to Compute Matrix **Dissimilarity**

### **Methods Insensitive to Spatial Distribution**

1. Root Mean Standard Error



2. Euclidean Distance



3. Two- Sample Kolmogorov-**Smirnov Test** 


### **Methods Sensitive to Spatial** Distribution

Drug X

Synergy Matrix-

△ Bliss


4. Syrjala Test <sup>4</sup>



Using these metrics, dissimilarity was computed for comparing all pairs of drug combinations


# Q1: Visualizing Dissimilarity in an Assay


Malaria Assay ID 1764: screening 480 drug combinations Similar- more red; Dissimilar- more yellow




# Q2: Chemical Structure Correlated with **Combination Response and Synergy**

Visualizing Dissimilarity of Method: compare Structures in an Assay corresponding x and y compounds









# Q3: Dose Response Correlated with **Combination Response and Synergy**

Visualizing Dissimilarity of Method: compare Dose Responses in an Assay corresponding x and y dose responses <sup>5</sup> Dose Response Dissimilarity



Dose Response Dissimilarit



Dose Response Dissimilarity

# Conclusion

### **Individual Compounds:**

- Structural similarity suppose to correlate to dose response similarity
- Correlation not shown  $(R^2 = 0.014; no correlation)$
- Suggests that using dose response as the compound property does not illustrate the SPP well

### **Drug Combinations:**

|               | Structural     | Dose Response  |
|---------------|----------------|----------------|
|               | Dissimilarity  | Dissimilarity  |
| Combination   | $R^2 = 0.020$  | $R^2 = 0.437$  |
| Response      | no correlation | correlation    |
| Dissimilarity |                |                |
| ∆ Bliss       | $R^2 = 0.006$  | $R^2 = 0.052$  |
| Dissimilarity | no correlation | no correlation |
|               |                |                |

- For SPP to hold, both have to correlate- this is not the case
- Correlations with Δ Bliss even weaker than response
- Means SPP does not seem to hold
- Suggests that understanding drug combinations is more complex than understanding individual compounds


### Discussion

#### Limitations

- Dose response was not a compound property that illustrated the SPP well
- Will be able to draw better conclusions about if the SPP for drug combinations using a different compound property

#### **Future Work**

- Clustering of response matrices- group together the drug combinations based on which show similar response matrices
- Work on SPP within specific clusters
- Perform more analysis:
  - Data for other medical conditions in addition to this work on Malaria,
  - Larger overall volume of data



### References

- <sup>1</sup> Nikolaus J. Sucher (2014). Searching for synergy in silico, in vitro and in vivo. *Synergy*, 1(1), 30-43.
- <sup>2</sup> Yvonne C. Martin, James L. Kofron, Linda M. Traphagen (2002). Do Structurally Similar Molecules Have Similar Biological Activity? Journal of Medicinal Chemistry, 45 (19), 4350-4358.
- <sup>3</sup> Rajarshi Guha, John H. Van Drie (2008). Structure-Activity Landscape Index: Identifying and Quantifying Activity Cliffs. Journal of Chemical Informatics and Modeling, 48(3), 646-658.
- <sup>4</sup> Stephen E. Syrjala, (1996). A Statistical Test for a Difference between the Spatial Distributions of Two Populations. *Ecology, 77*(1), 75-80.
- <sup>5</sup> Lawrence I-Kuei Lin. (1989). A Concordance Correlation Coefficient to Evaluate Reproducibility. *Biometrics, 45*(1), 255-268.